Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $365,000.

  • Northwest Biotherapeutics' Other Non-Current Assets fell 4.28% to $358,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $358,000, marking a year-over-year decrease of 4.28%. This contributed to the annual value of $365,000 for FY2024, which is 1.11% up from last year.
  • Northwest Biotherapeutics' Other Non-Current Assets amounted to $365,000 in FY2024, which was up 1.11% from $361,000 recorded in FY2023.
  • Northwest Biotherapeutics' 5-year Other Non-Current Assets high stood at $1.0 million for FY2021, and its period low was $345,000 during FY2022.
  • Moreover, its 3-year median value for Other Non-Current Assets was $361,000 (2023), whereas its average is $357,000.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Other Non-Current Assets rose by 19.49% in 2021, and later slumped by 66.70% in 2022.
  • Northwest Biotherapeutics' Other Non-Current Assets (Yearly) stood at $867,000 in 2020, then climbed by 19.49% to $1.0 million in 2021, then crashed by 66.70% to $345,000 in 2022, then increased by 4.64% to $361,000 in 2023, then climbed by 1.11% to $365,000 in 2024.